AstraZeneca's (AZN) Q4 Earnings And Sales Miss Estimates
Zacks Investment Research | Feb 13, 2020 09:21PM ET
AstraZeneca (NYSE:AZN) reported dismal fourth-quarter results with earnings and sales both missing the Zacks Consensus Estimate. The company issued revenue and earnings guidance for 2020. It expects coronavirus outbreak in China to unfavorably impact its sales and profits in 2020.
Shares of AstraZeneca were down almost 1.8% in pre-market trading on Feb 14 following the dismal fourth quarter results. However, the company’s shares have rallied 20.5% in the past year compared with the industry ’s increase of 9.2%
Earnings & Sales Miss
Fourth-quarter 2019 core earnings of 45 cents per American depositary share missed the Zacks Consensus Estimate of 53 cents. Core earnings per share of 89 cents declined 46% year over year at constant exchange rates (“CER”).
Total revenues were up 4% (5% at CER) to $6.66 billion in the reported quarter, driven by higher product sales. Revenues, however, missed the Zacks Consensus Estimate of $6.71 billion.
All growth rates mentioned below are on a year-over-year basis and at CER.
Product Sales Rise
Product sales rose 9% at CER to $6.25 billion. Higher sales of newer medicines and higher sales in emerging markets offset lower sales of many other legacy medicines.
Collaboration revenues (formerly Externalization revenues) were $414 million, down 36% year over year.
Among AstraZeneca’s various therapeutic areas, Oncology was up 29%, New Cardiovascular, Renal and Metabolism was up 7%, BioPharmaceuticals was up 11%, and Respiratory rose 14%. However, other medicines declined 16%.
Newer Products Drive Sales
Among the newer medicines, Lynparza sales rose 69% year over year and 7.3% sequentially to $351 million in the quarter on the back of expanded use in ovarian and breast cancer, as well as solid growth in emerging markets. AstraZeneca markets Lynparza in partnership with Merck (NYSE:MRK) .
Tagrisso recorded sales of $884 million, up 49% year over year driven by continued underlying demand growth and strong uptake in the first-line setting for lung cancer as it is the standard of care. Sales increased 2% sequentially in the U.S. market.
Imfinzi generated sales of $424 million in the quarter, up 62% year over year mainly driven by strong demand in lung cancer patients. Like the previous quarters, the vast majority of Imfinzi’s sales came from the United States and the lung cancer indication.
Calquence, which was launched in the United States in October 2017, generated sales of $56 million in the fourth quarter compared with $44 million in the previous quarter.
Brilinta/Brilique sales were $428 million in the reported quarter, up 15% year over year driven by continued patient uptake in acute coronary syndrome and high-risk post-myocardial infarction indications.
Farxiga recorded sales of $419 million in the quarter, up 7% year over year.
Asthma medicine Fasenra recorded sales of $206 million in the quarter, up 65% year over year. AstraZeneca said Fasenra enjoys leadership position among novel biologic asthma medicines in top five European countries and Japan.
Bevespi, a LAMA/LABA in a pressurized metered dose inhaler, recorded sales of $12 million in the quarter, compared to $10 million recorded in the previous quarter, amid slower-than-anticipated growth in LAMA/LABA class.
Among other medicines, Bydureon sales were up 1% to $139 million. Seloken sales increased 20% to $190 million. However, Iressa sales were down 28% to $80 million. Onglyza sales declined 10% to $131 million and Byetta sales were down 15% to $27 million.
Older Products
Crestor sales declined 15% to $296 million. U.S. and Europe sales were weak as multiple generic versions of the drug entered the market.
Symbicort sales were up 13% in the quarter to $712 million while Pulmicort sales rose 7% to $413 million.
Nexium recorded sales of $353 million, down 10% due to lower sales in the United States. Sales of other legacy drugs including Zoladex, Arimidex, Atacand and Daliresp/Daxas grew in the quarter while sales of others like Faslodex, Casodex, and Synagis declined.
Regional Performance
In the United States, product sales were up 1% to $2.1 billion. Sales in European markets grew 4% in the fourth quarter to $1.18 billion. Revenues from Emerging Markets were up 20% to $2.1 billion, primarily on the back of strong growth in China (up 28% to $1.19 billion).
In Established ROW market (comprising Japan, Canada and other markets), sales were up 13% to $918 million.
Profit Discussion
AstraZeneca’s core gross margin declined two percentage points (at CER) to 77.5%. Core selling, general and administrative (SG&A) expenses rose 9% to $2.63 billion.
In the quarter, core research and development (R&D) expenses rose 4% to $1.5 billion. Core operating profit declined 33% to $1.55 billion in the quarter. Core operating margin decreased 12 percentage points to 23.2% in the quarter.
2020 View
AstraZeneca issued its guidance for total revenues and core EPS for 2020. The company expects total revenues to grow by a high single digit to a low double digit. The company expects core EPS guidance to increase by a mid- to high-teens percentage.
The company stated that the guidance takes into account the unfavorable impact of the recent coronavirus outbreak and expects it to last for a few months. It plans to provide an updated guidance on its first-quarter 2020 earnings call, after gaining an insight on the actual impact of the coronavirus outbreak.
AstraZeneca PLC Price, Consensus and EPS Surprise
Get The News You Want
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.